Can existing drugs stop COVID-19 from getting worse?
NCT ID NCT04581954
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This study tested two drugs, ruxolitinib and fostamatinib, in hospitalized adults with mild to moderate COVID-19 pneumonia. The goal was to see if either drug could prevent the disease from becoming severe. 185 patients were randomly assigned to receive one of the drugs or standard care for 14 days, and their progress was tracked for 28 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Imperial College Healthcare NHS Trust
London, W12 0HS, United Kingdom
-
London North West University Healthcare
London, HA1 3UJ, United Kingdom
-
Royal Berkshire NHS Foundation Trust
Reading, RG1 5AN, United Kingdom
-
Sheffield Teaching Hospitals NHS Foundation Trust - Royal Hallamshire Hospital
Sheffield, S10 2JF, United Kingdom
-
The Leeds Teaching Hospital - St James University Hospitals NHS Trust
Leeds, LS9 7TF, United Kingdom
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ruxolitinib and fostamatinib
What this could lead to
If successful, these drugs could offer a new treatment option to prevent severe COVID-19 pneumonia in hospitalized patients.
What could go wrong
This was a relatively small, early-phase trial (Phase 1/2) with 185 participants, so results may not apply to everyone. The drugs also have known side effects like infection risk.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.